Christopher Finch

Christopher is our Vice President of Corporate Development and Strategy.

Prior to joining Oruka, he spent seven years at CRISPR Therapeutics, most recently serving as Head of Strategy. During his time at CRISPR, his responsibilities spanned strategy, business development, alliance management, new product planning, competitive intelligence, and other corporate activities. He made key contributions to the company’s strategy and executed multiple strategic collaborations as CRISPR grew from research to commercial stage with the approval of the first ever CRISPR-based product, CASGEVY™. Before joining CRISPR, he worked as a consultant at McKinsey & Company where he served clients in the biopharma industry.

He studied algal biotechnology as a Churchill Scholar at the University of Cambridge, where he received his MPhil, and he received a BA in Biochemistry and Biophysics from Amherst College.